<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02722083</url>
  </required_header>
  <id_info>
    <org_study_id>18573</org_study_id>
    <nct_id>NCT02722083</nct_id>
  </id_info>
  <brief_title>Exploratory Study for Allergy Relief Onset</brief_title>
  <official_title>A Single-blind, Randomized, Placebo Controlled, Crossover Pilot Study to Evaluate the Onset of Action of an Antihistamine in Subjects Following Allergen Exposure in an Allergen Chamber</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to explore the onset of effect of an antihistamine in a
      controlled environment.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date type="Actual">May 7, 2016</start_date>
  <completion_date type="Actual">July 13, 2016</completion_date>
  <primary_completion_date type="Actual">May 27, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The time to the meaningful relief, as defined by at least 15% of reduction from baseline in Total Symptom Score (TSS)</measure>
    <time_frame>4 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events as a measure of safety</measure>
    <time_frame>3 month</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Rhinitis, Allergic</condition>
  <arm_group>
    <arm_group_label>BAY X002134</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be given BAY X002134</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will be given a placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chlorpheniramine maleate (BAY X002134)</intervention_name>
    <description>4 mg tablet, single dose, orally</description>
    <arm_group_label>BAY X002134</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo tablet, single dose, orally</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ambulatory healthy male and female subjects between 18 to 65 years of age inclusive;

          -  Self-reported to have seasonal allergic rhinitis for at least 2 years prior

          -  Documented positive skin prick test response to common ragweed (ambrosia
             artemisiifolia) pollen; prick with wheal &gt; 4mm larger than the diluent within the
             previous 12 months

          -  Total Symptom Score (TSS) ≥ 40 mm at the 90 or 120 minute time point during one of the
             Priming Visits and at 90 or 120 minute time points during ragweed challenge Symptom
             Induction Phase of each Treatment Visit;

          -  Body Mass Index (BMI) in the range of 18 to 30 kg/m2

          -  Female subjects of childbearing potential must be using a medically acceptable form of
             birth control for at least 1 month prior to screening (3 months on oral
             contraceptives), e.g., oral or patch contraceptives, intrauterine device, injectable
             contraceptive (e.g. Depo-Provera®), or a double barrier and have a negative pregnancy
             test at Screening and prior to IMP administration on Day 1 and Day 7 ± 1 day. Female
             subjects of non-childbearing potential must be amenorrheic for at least two years or
             had a hysterectomy and/or bilateral oophorectomy

        Exclusion Criteria:

          -  Evidence or self-reported history of significant medical condition which, in the
             judgment of the investigator, is a contraindication to the use of chlorpheniramine, or
             might interfere with the trial. These may include thyroid disease (e.g.,
             hyperthyroidism, hypothyroidism), uncontrolled diabetes mellitus, coronary heart
             disease, ischemic heart disease , symptomatic prostatic hypertrophy, bladder neck
             obstruction, hepatic insufficiency, narrow-angle glaucoma, pyloroduodenal obstruction,
             or stenosing peptic ulcer;

          -  Known allergy to chlorpheniramine, dexchlorpheniramine, or any of its inactive
             ingredients

          -  Self-reported non-responders (lack of therapeutic effect) to antihistamines

          -  Administration of epinephrine is contra-indicated;

          -  Current use of oral steroids, including prednisone and prednisolone;

          -  Females who are pregnant or lactating

          -  A history of anaphylaxis to ragweed allergen

          -  Subjects with a history of asthma, lower respiratory tract disease, emphysema or
             chronic bronchitis; At the discretion of the investigator, subjects with self-reported
             mild intermittent asthma or exercise induced asthma may be included.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <link>
    <url>http://pharma.bayer.com/en/innovation-partnering/clinical-trials/trial-finder/</url>
  </link>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 23, 2016</study_first_submitted>
  <study_first_submitted_qc>March 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 29, 2016</study_first_posted>
  <last_update_submitted>May 18, 2017</last_update_submitted>
  <last_update_submitted_qc>May 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chlorpheniramine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

